Upload
kreiter
View
472
Download
2
Tags:
Embed Size (px)
DESCRIPTION
Overview over CIMT activities and structure
Citation preview
Association for CANCER IMMUNOTHERAPY (CIMT)
1
29. DEUTSCHER KREBSKONGRESSBerlin 24. – 27. Februar 2010
Individualisierte Immunintervention in der Tumormedizin
www.cimt.eu
H.-G. Rammensee
C.Huber
G.Schuler
P. Johnson
C.Melief
U.Kalinke
P. Walden
Executive Board
CIMT – The People
Scientific Secretaries Local Organizers
C. Britten
S.Kreiter
T. Seppman
M. Diken
2
Scientific Advisory Board
P. Beckhove P. Bossart U. Keilholz
C. Ottensmeier G. Parmiani U. Sahin
M. Schmitt J. Schultze H. Singh
F. Stevenson T. Tüting T. Wölfel
3
CIMT – The Goals
To enhance development of cancer immunotherapy by:
1. Facilitating cooperation between academia, biotech, pharma and __regulatory agencies in the field of Scientific and Technical Research
o Scientific conferences, Working parties, Proficiency Panel Program
2. Education of health professionals and patients self-help __organizations
o Advanced education conferences & textbookso Patient Academy Cancer Immunotherapy
3. Cooperation with partners
o Consortia, Universities, Regulatory agencies, Scientific Journals, Foundations and Companies
o Patients advocacy groups
CIMT – The Organigramm
4
Executive Board
Scientific advisory Board
Scientific Secretaries
Communications Director
Annual MetingRegulatory Research
Group
CIMT Immunoguiding
Program
Patient Academy
Local Organizers
Adminstration
Annual Meetings
CIMT – The Annual Meetings
5
• Basic and translational tumor immunology
• >350 participants from academia, companies and regulatory authorities
• From >15 countries• > 100 abstracts• Working parties CIP & RRP• Industry workshops
CIMT – Annual Meeting 2009
6
Regulatory Research Group
Chair: U. Kalinke
Members: H. Singh, U. Sahin, J. Müller-Berghaus, T. Hinz, K.J. Kallen, C. Britten, S. Kreiter
7
CIMT – Regulatory Research Group
CVC Delegate
A. Hoos
Scientific Sessions
Comments to Guidelines
Co-operationsResearch Projects
EMEA Comments and suggestions regarding the planned implementation of the “Advanced
Therapy Medicinal Prodcuts „Regulation (EC) No 1394/2007 (7th July 2008)
FDA Draft Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines (16th Dec. 2009)
C. Gouttefangeas
C. Britten
S. Van der Burg
(Current Chair)
C. Ottensmeier
M. Welters
M. Kalos
8
CIMT – Immunoguiding Program (CIP)
Workshops + Scientific Sessions
Co-operation with other groups
Proficiency Panel Program
Dissemination of Datav
Services
HLA-peptideMultimers
ELISPOT Intracellular Cytokine Staining
25 participating labs (36 labs on the waiting list) 8 (11) European countries Mainz, Leiden, Tübingen (main organizers) Southampton, Copenhagen, Berlin (co-organizers)
CIP – Proficiency Panel Programm
Immune response Tumor size Patient survival
timeTreatment
early late
10
CIMT – Immunoguding Program (CIP)
T cell Immunomonitoring Imaging Techniques Clinical Endpoints
Announced in Immunity: www.miataproject.org
11
CIP – Minimal Information About T cell Assays
First consensus workshop will take place in Washington on
March 19th. Workshop is hosted by CRI-CVC and CIP.
Stem celltransplantation
2007 2010
12
CIMT – Educational Aspects
Education of health professionals & patients
o Advanced education meetings in collaboration with ESO-Do Patients Cancer Immunotherapy Academyo Text books
13
CIMT – Partners and Sponsors
Visit CIMT !
1414
CIMT – Safe The Date ! (May 26th-28th, 2010)
CIMT Homepage
o www.cimt.eu
CIMT on Twitter
o http://twitter.com/C_IMT
CIMT on facebook
o www.facebook.com/pages/CIMT-Association-for-Cancer-Immunotherapy/310545294710